plc (NYSE: MNK) today announced that its subsidiary, Cadence
Pharmaceuticals, Inc., has entered into settlement and license
agreements with Fresenius Kabi USA, LLC, resolving pending patent
litigation involving OFIRMEV ® (acetaminophen) injection.
for - Mallinckrodt Pharmaceuticals Announces Settlement of OFIRMEV® (acetaminophen) Injection Patent Litigation with Fresenius Kabi USA, LLC investment picks